![Rallybio Profile](https://pbs.twimg.com/profile_images/1667227334460448791/krA8DOho_x96.jpg)
Rallybio
@rallybio
Followers
111
Following
16
Statuses
170
We are committed to discovering and developing life-transforming therapies for people with severe and rare diseases. Community guidelines: https://t.co/0p7mwSWuK7
New Haven, CT
Joined September 2021
#MaternalHealthAwaresnessDay we reflect on how Rh disease is nearly eradicated thanks to innovation & early detection. At Rallybio, we're working to do the same for FNAIT. Together, we can transform #maternalhealth with better testing & treatments. #RLYB116
0
1
1
Thanks to @ScripEleanor and @PharmaScrip for including our Founder & Chairman Martin Mackay’s thoughts on Eroom’s law & how the FDA can plan for an influx of pending drug submissions in this piece on what’s to come for biopharma in 2025!
0
0
2
This January, we’re raising awareness for #BirthDefectsAwarenessMonth and advancing solutions for maternal and fetal health. Learn more from organizations like the @NBDPN.
0
0
1
🩺 RLYB116: PK/PD study launch (Q2), Cohort 1/2 data readouts (Q3, Q4) 🧑⚕️ REV102: IND activities (Q1), Preclinical data (2H 2025) Here’s to another year of pushing boundaries to bring transformative therapies to those who need them most. #RareDisease #2025Goals (2/2)
0
0
1
As we work to improve maternal and fetal health outcomes, we're inspired by this year’s roadmap on biomarker science, clinical study design, and data analysis, fostering collaboration and innovation in maternal care. Read more here: #WomensHealth
0
0
1
Were you able to make it to @ASH_hematology this year? If so, you may have seen some exciting new data from the Rallybio pipeline shared throughout the weekend on RLYB212 and RLYB332! Check out both posters on our site here:
0
1
3
Our CFO Jon Lieber proudly represented Rallybio at last night's #Fierce50 Gala, where we were an Innovation honoree! 🥂 We have much to look forward to next year and are another step closer to transforming lives. Thank you, @FiercePharma! #RareDisease
0
1
5
We discussed recent updates and our plans to advance RLYB116, an innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor in development for the treatment of patients with complement-mediated diseases. #RLYB116 #RareDisease
0
1
3